No increased risk of birth defects in children of fathers treated for testicular cancer

New research has found no increased risk of congenital malformations associated with treatment with radiotherapy or chemotherapy in children of fathers with testicular cancer. The study, by Yahia Al-Jebari of Lund University, Sweden and colleagues, is published in the open-access journal PLOS Medicine on June 4, 2019. It followed 4,207 children of 2,380 fathers and finds that those conceived after treatment were not at a greater risk of congenital malformations than those conceived before.

Radiotherapy and chemotherapy have been shown to cause mutations and genetic damage in animal and human sperm and there has been concern that men treated with those therapies could have an increased chance of having children with genetic disease or birth defects. Because testicular cancer affects younger men, the team were able to compare children conceived before and after their fathers received treatment.

The study data were from Swedish national birth registries, with 2 million Swedes born between 1994 and 2014. Limitations are a lack of data on frozen or donor sperm, and only a limited number of patients were treated with radiotherapy and high doses of chemotherapy. However, even for those children, no increased risk was detected.

The research does suggest a slightly raised risk associated with the fathers’ testicular cancer, regardless of treatment, but that increase was small, from 3.5 to 4.4 children in every 100 born, and should not be a worry to patients.

Yahia Al-Jebari says: “Our research set out to investigate whether treatment for the most common cancer among young men leads to a higher risk of fathering a child with a birth defect and we saw no increased risk associated with cancer therapies. We did see a slightly raised risk to children of these fathers but this was only very small and was not associated with treatment given. Patients should be reassured that this is not a cause for concern.”

###

Research Article

Funding:

The study was supported by funds from ReproUnion (EU Interreg V program, grant number: DNr. 6.3.3 – Å 2018 – 1612, website: http://reprounion.eu/), Swedish Cancer Society (grant number: CAN 2017/413, website: https://www.cancerfonden.se/), Swedish Childhood Cancer Society (grant number: KP2018-0020, website: https://www.barncancerfonden.se/), Swedish Governmental Funding (ALF, grant number: N/A, website: https://www.skane.se/), Malmö University Hospital Cancer Fund (grant number: N/A, website: https://www.cancerforskningmalmo.se/), and Nordic Cancer Union (grant number: 1449585341315, website: http://ncu.nu/). All funds were granted to AG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests:

The authors have declared that no competing interests exist.

Citation:

Al-Jebari Y, Glimelius I, Berglund Nord C, Cohn-Cedermark G, Ståhl O, Tandstad T, et al. (2019) Cancer therapy and risk of congenital malformations in children fathered by men treated for testicular germ-cell cancer: A nationwide register study. PLoS Med 16(6): e1002816. https://doi.org/10.1371/journal.pmed.1002816

Image Credit: Ed Uthman, Flickr

Author Affiliations:

Molecular Reproductive Medicine, Department of Translational Medicine, Lund University, Malmö, Sweden

Department of Medicine, Division of Clinical Epidemiology, Karolinska Institute, Stockholm, Sweden

Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

Department of Oncology-Pathology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden

Department of Oncology, Skåne University Hospital, Lund, Sweden

Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway

The Cancer Clinic, St. Olav’s University Hospital, Trondheim, Norway

Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark

Department of Oncology, University Hospital of North Norway, Tromsø, Norway

Institute of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway

Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

Division of Occupational and Environmental Medicine, Lund University, Lund, Sweden

In your coverage please use this URL to provide access to the freely available paper: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002816

Media Contact
PLOS Medicine
medicinepress@plos.org
http://dx.doi.org/10.1371/journal.pmed.1002816

Comments